Kornimate/medical-research-clean huggingface dataset:
positive expiratory pressure during inhalation of hypertonic saline in patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this trial aims to analyze whether the inhalation of hypertonic saline combined with a positive expiratory pressure (pep) device increases the amount of sputum expectorated during the chest physiotherapy session ( inhalation + bronchial drainage).

all patients will perform two different arms of treatment in a crossover randomization. each arm of treatment will be applied during 5 consecutive days. the wash-out period will be one week. before starting the trial all patients will do an inhalation formation. during the study period the patients' pharmacological treatment remains unchanged

Eligibility criteria:
inclusion criteria: * pass the inhalation test * chronic sputum production, at least ≥ 10 ml /24h * cystic fibrosis (cf) diagnosed ( established by genotype or sweat sodium\>70 mmol/l or sweat chloride of\>60 mmol/l) * clinically stable at the time of recruitment (defined as no requirement for antibiotics or change in respiratory medication in the preceding 4 weeks) * trained in the use of autogenic drainage technique (at least 6 months) * inhaling hypertonic saline since at least 6 months * to be able to provide written, informed consent and perform the protocol and the evaluations exclusion criteria: * active massive hemoptysis during the previous 2 months * patient in transplantation or retransplantation list * patient already participating in another study at the same time

Keywords: hyperosmolar agents hypertonic saline airway clearance techniques positive expiratory pressure autogenic drainage
premature aging and type 2 diabetes mellitus: an increased risk of cardiomyopathy?

Conditions: Type 2 Diabetes Mellitus

Summary: the potential clinical implications of this study are to optimise the selection of a population at risk for developing a diabetic cardiomyopathy among diabetic patients in order to develop early therapeutic strategies to prevent the left ventricular remodelling. therefore, the originality of this project is to hypothesize that : * diabetes mellitus is often associated with a premature aging syndrome * cellular senescence may potentiate the mechanisms that are involved in decreasing myocardial contractility in dm and, * dm associated to premature aging may increase the risk of developing a cardiomyopathy thus, the modulation of telomerase activity and the control of telomere length, together with the attenuation of the formation of reactive oxygen species, might represent important new targets in order to develop therapeutic tools in prevention of diabetic cardiomyopathy.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * 40 \< age \< 55 years old * oral antidiabetic or insulin treatment * no symptoms * sinus rhythm * no sign or history of heart disease * lvef \> 55% * absence of regional left ventricular motion abnormalities. exclusion criteria: * absence of sinus rhythm, * silent ischemia defined as positive exercise test or positive stress echocardiography, * history of cardiomyopathy or cad, * valvular heart disease hemodynamically significant, * severe renal insufficiency defined as creatinine clearance \< 30 ml/min, * echocardiographic images unsuitable for quantification, * type 1 diabetes mellitus, * important diabetes mellitus imbalance defined as glycated hemoglobin \> 9% or glycemia \> 3g/l uncontrolled hypertension (\> 180/100 mmhg).

Keywords: diabetes mellitus accelerated aging cellular senescence diabetic cardiomyopathy strain imaging strain rate imaging, echocardiography
effect of nmn supplementation on organ system biology

Conditions: Glucose Metabolism Disorders

Summary: the goal of this proposal is to determine whether the beneficial effects of nmn on metabolic function observed in rodents applies to people.

this study is looking at the effect of the dietary supplement "nicotinamide mononucleotide" (nmn) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease.

Eligibility criteria:
inclusion criteria: * bmi 25.0-50.0 kg/m² * prediabetes defined as fasting plasma glucose of ≥100 mg/dl, or hba1c ≥5.7, or homa-ir ≥2.5. exclusion criteria: * women who are still having menses * persons who take niacin, nicotinamide, or other vitamin b3-related supplementation and are not willing to discontinue supplementation for 3 weeks before medical screening and during the entire study period * persons who consume moderate-large amounts of caffeine daily (\>2 cups of coffee or 8 oz caffeinated drinks per day) or consume less amounts of caffeine but believe withdrawal symptoms (e.g. headache) are likely if caffeine is stopped * unstable weight (\>3% change during the last 2 months before entering the study)
autonomic state, cardiovascular control and outcomes in coronary surgery

Conditions: Atrial Fibrillation; Acute Kidney Injury

Summary: characterization of the perioperative autonomic nervous system state, cardiovascular and cerebrovascular control and microcirculation in order to predict postoperative atrial fibrillation and acute kidney injury in patients undergoing coronary artery bypass graft surgery

atrial fibrillation (af) and acute kidney injury (aki) are common postoperative complications in patients undergoing coronary artery bypass graft (cabg) surgery. aki increases postoperative mortality and af prolongs the hospital stay. autonomic dysfunction, baroreflex impairment and an inadequate microvascular perfusion may play a relevant role in triggering af and aki. the perioperative characterization of the autonomic nervous system (ans) and of the microcirculation might improve risk stratification and help in the prevention and early treatment of af and aki in cabg surgery. the study aims are: i) to collect a number of perioperative indices describing the state of the ans and of the microcirculation; ii) to assess the correlation among the different indices and their association with af and aki; iii) to develop a predictive model of postoperative outcomes (af and aki) accounting for perioperative autonomic indices and microcirculatory variables. population: 200 adults subjects scheduled for cabg surgery, with or without additional intervention methods: perioperative (in the operating room) acquisition of ecg, arterial blood pressure, cerebral blood flow velocity as derived from transcranial doppler technique, microcirculation parameters as derived from sidestream dark field images statistics: receiver operating characteristic (roc) curve analysis with adequate cut-off values

Eligibility criteria:
inclusion criteria: * age over 18 * sinus rhythm * absence of pathologies affecting autonomic nervous system (e.g. diabetes with neuropathy) * informed consent signed * elective or urgent surgery exclusion criteria: * age under 18 * absence of sinus rhythm * pathologies affecting autonomic nervous system * emergency surgery (to be operated immediately)

Keywords: autonomic nervous system atrial fibrillation acute kidney injury baroreflex sensitivity microcirculation coronary artery bypass graft
a study to evaluate the efficacy of gsk biologicals' influenza vaccine in children

Conditions: Influenza

Summary: this study is designed to test the efficacy of an investigational influenza vaccine, in children compared to havrix®, a licensed hepatitis a virus vaccine. this study will also evaluate the immunogenicity and safety of the investigational vaccine.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that they and/or their parent(s) or legally acceptable representative(s) can and will comply with the requirements of the protocol. * a male or female child aged between 3 and 8 years inclusive at the time of the first vaccination; children are eligible regardless of history of administration of influenza vaccine in a previous season. however, subjects who have received any seasonal or pandemic influenza vaccine within 6 months preceding the first dose of study vaccine will not be enrolled. * written informed consent obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject. * written assent obtained from the subject if/as required by local regulations. * subjects in stable health as determined by investigator's clinical examination and assessment of subjects' medical history. * access to a consistent means of telephone contact exclusion criteria: * child in care. * use of an investigational or non-registered product other than the study vaccines within 30 days before study vaccination or planned use during study period. routine registered childhood vaccinations are permitted. * prior receipt of any seasonal or pandemic influenza vaccine within 6 months preceding the first dose of study vaccine, or planned use of such vaccines during the study period. prior receipt of more than one dose of a licensed hepatitis a vaccine, with the first dose administered at \>=12 months of age. * chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose. * administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period. * history of guillain-barre syndrome within 6 weeks of receipt of prior influenza virus vaccine. * any known or suspected allergy to any constituent of influenza vaccines ; a history of anaphylactic-type reaction to constituent of vaccine; or a history of severe adverse reaction to a previous influenza vaccine. * fever at the time of enrolment. * acute disease at the time of enrolment. * any significant disorder of coagulation or treatment with coumadin derivatives or heparin. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * ongoing aspirin therapy. * any other condition which, in the opinion of the investigator, prevents the subject from participating in the study.

Keywords: influenza
an international cross-sectional survey to evaluate the burden of fibrodysplasia ossificans progressiva (fop) on patients and their families.

Conditions: Fibrodysplasia Ossificans Progressiva

Summary: the fop burden of illness (boi) survey aims to assess the impact of the burden of fop on patients and their families. the study is being conducted online and available for residents in argentina, brazil, canada, france, germany, italy, japan, mexico, poland, russia, south korea, spain, sweden, the us, and the uk.


Eligibility criteria:
inclusion criteria: 1. individuals meeting one of the two categories below (a or b) are eligible to participate: a. any individual with fop, of any age; b. any individual who is a family member of a person with fop (i.e. either a parent / legal guardian or a sibling) and who is aged 18 years and older 2. all adult participants and parents / legal guardians of minors should provide informed consent before starting filling out the survey exclusion criteria: 1. any individuals who are unable to complete the online survey independently or to get assistance to physically enter the answers
current status of diagnosis, treatment and quality of life for patients with idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the goal of this observational study is to explore current status of diagnosis, treatment and quality of life for patients with idiopathic pulmonary fibrosis. it aims to integrate qualitative and quantitative data to describe the distribution of perspective, experience, patient journey, treatment, expectation and quality of life for patients with idiopathic pulmonary fibrosis. participants will be invited to participate the interview, and answer quantitative survey questions about their quality of life.

idiopathic pulmonary fibrosis (ipf) is a rare, progressive, fibrotic interstitial lung disease of unknown aetiology primarily affecting middle-aged and elderly patients, more men than women. median survival is 3∼5 years from the time of diagnosis. the prognosis is worse than for most common malignancies. however, patients' experiences, quality of life and needs during the disease course, have not been adequately investigated, which leads a lack of evidence to support the priority of treatment or drug development. this study plans to conduct an mixed methods research to integrate qualitative and quantitative data to explore the perspective, experience, patient journey, treatment, expectation and quality of life for patients with idiopathic pulmonary fibrosis. for qualitative interview, there are 50 patients with idiopathic pulmonary fibrosis, and 15 physicians will be interviewed. for quantitative survey, there are 245 patients with idiopathic pulmonary fibrosis will be involved.

Eligibility criteria:
inclusion criteria: * ipf patients who are diagnosed according to international guidelines. * physicians who are clinical experts with extensive experience in the treatment of ipf. exclusion criteria: - the patient is unable to express his/her opinion clearly.

Keywords: idiopathic pulmonary fibrosis rare disease quality of life mixed methods
levels of endocan in umbilical cord blood samples of pregnant females with intrauterine growth retardation

Conditions: Intrauterine Retardation

Summary: as a proteoglycan secreted from endothelial cells, expression, and secretion of endocan increases in the endothelium of several tissues secondary to inflammation. it can be regarded as an indicator of endothelial damage. besides, it is both a target and a modulator of the vascular endothelial growth factor (vegf) signaling pathway. considering its action mechanisms, it can provide information about angiogenesis, inflammation, and vascular permeability. it is known that intrauterine growth retardation mainly occurs as a result of endothelial dysfunction and abnormal angiogenesis in the placenta. in previous studies, maternal serum endocan levels have also been shown to be increased in cases of preeclampsia, which is mainly characterized by placental dysfunction.so, we hypothesize that there may be an association between endocan levels and intrauterine growth retardation.

endocan is a proteoglycan that is closely associated with inflammation. its levels increase in association with the severity of endothelial damage. endothelial dysfunction and abnormal angiogenesis in the placental tissues are the main pathophysiological mechanisms leading to intrauterine growth retardation. it has been known that there was a significant association between maternal serum levels of endocan and preeclampsia. in cases with preeclampsia, increased serum levels of endocan in maternal blood samples has been reported. intrauterine growth retardation is a situation in which endothelial dysfunction and abnormal angiogenesis are the leading disturbances. in fetuses with intrauterine growth retardation, a hypoxic environment secondary to uteroplacental insufficiency. in previous studies, increased levels of endocan in maternal blood samples have been shown. although maternal blood can be a good reflector of situations both in fetuses and their mothers, measurement of endocan in umbilical cord blood samples may better represent the pathology in fetuses.

Eligibility criteria:
inclusion criteria: for "intrauterine growth retardation" group: * consent to participate study * detection of intrauterine growth retardation during follow up of pregnancy for "healthy fetuses" group: * consent to participate study * absence of intrauterine growth retardation during follow up of pregnancy exclusion criteria: * multiple pregnancy * presence of major developmental anomalies of fetuses * detection of chromosomal anomalies * malnourished mothers * vegetarian diet of mothers * use of cigarette and alcohol during pregnancy * previous history of stillbirths

Keywords: intrauterine growth retardation umbilical cord blood proteoglycans pregnancy outcomes
a study of tocilizumab as monotherapy or in combination with dmards in patients with moderate to severe active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this open-label single-arm study will evaluate the safety, tolerability and efficacy of tocilizumab \[roactemra/actemra\] in patients with moderate to severe rheumatoid arthritis who experience an inadequate clinical response to a stable dose of non-biologic disease modifying anti-rheumatic drugs (dmard) or anti-tumor necrosis factors (tnfs). roactemra/actemra will be administered as a monotherapy or in combination with dmards. roactemra/actemra will be administered as intravenous infusion at a dose of 8 mg/kg every 4 weeks for a total of 6 infusions. the anticipated time on study treatment is 24 weeks. the target sample size is 50-150 patients.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * moderate to severe rheumatoid arthritis (das28 \>3.2) of 6 months duration * inadequate clinical response to non-biologic dmards or anti-tnf * bodyweight \</=150 kg exclusion criteria: * rheumatic autoimmune disease or inflammatory joint disease other than ra * major surgery within 8 weeks prior to screening or planned major surgery within 6 months following screening
efficacy of ketorolac 0.4% in prostaglandin suppression

Conditions: Inflammation

Summary: a pilot study to evaluate the extent of pge2 inhibition (mean aqueous values) by ketorolac 0.04% following peripheral iridotomy


Eligibility criteria:
inclusion criteria: * patients scheduled to undergo phakic iol implantation exclusion criteria: * history of intraocular surgery in the operative eye
corneal opacities in children

Conditions: Corneal Opacities

Summary: a prospective observational study on corneal opacities in infants and children (1 month to 18 years old) will be conducted at chla. most of these cases will be due to congenital corneal opacity (e.g. peter's anomaly, mucopolysacharidoses) or scarring due to infectious keratitis. sixty (60) subjects will be recruited. the children will be examined under anesthesia with a portable slit-lamp and oct. an ivue oct system (optovue) attached to an operating microscope-style mount at chla will be used for the intraoperative scans. both cross-sectional and 3-d oct scans will be performed to assess opacity depth, pachymetry map, endothelial defects, and any abnormal adhesion between the cornea, iris and lens. the anterior chamber angle will also be imaged with cross-sectional oct to assess angle depth, trabecular meshwork, schwalbe's line, and possible peripheral iridocorneal adhesion or posterior embryotoxon. oct of the crystalline lens will be obtained to assess the presence of cataract. slit-lamp photography will be obtained, and gonioscopy will be performed if indicated. corneal diameter will be measured with a caliper, and intraocular pressure will be measured with a tonopen (reichert).


Eligibility criteria:
inclusion criteria: * infants and children (1 month to 18 years of age) with corneal opacity requiring a thorough eye examination. exclusion criteria: * inability to give informed consent. * inability to maintain stable fixation for oct imaging. * inability to commit to required visits to complete the study.

Keywords: corneal opacities optical coherence tomography
investigation of the effect of internet addiction level in university students

Conditions: University Students

Summary: the internet, which has become a part of our daily life; serves many purposes such as quick access to information, e-mail, and chat, banking and shopping, having a good time, using social networking sites. internet addiction, which was first defined by ivan goldberg in 1996, is defined as the inability to control internet use, which causes pressure, feelings of anxiety, and dysfunctional behaviors in daily life activities. social media, digital games and smartphone addiction are among the addiction types whose active ingredient is the internet, and internet addiction is expressed as a whole, regardless of the type of addictive application or activity. considering that internet use is common among young people, one of the risk groups in terms of internet addiction is university students. as a matter of fact, günay et al. stated that approximately 8% of university students are at risk of internet addiction. in the literature, musculoskeletal problems and pain in the thumb and related joints, reduction in pinch strength, and hand function have been reported with smartphone use. in addition, a significant relationship was found between the time spent surfing the internet and pain at the base of the thumb. however, to the best of our knowledge, no study has been found that examines the effect of internet addiction level on thumb pain threshold, hand strength and manual dexterity in university students. the aim of our research is to determine the level of internet addiction in university students and to examine the effect of internet addiction level on thumb pressure pain threshold, hand strength and manual dexterity.


Eligibility criteria:
inclusion criteria: * being between the ages of 18-25 * being a student at bandırma onyedi eylül university * willingness to participate in the study exclusion criteria: * any injury involving the upper extremity in the last 6 months * any surgical operation involving the upper extremity in the last 6 months * any systemic disease * any neurological problems * use of any psychiatric medication

Keywords: internet addiction pain threshold hand strength manual dexterity
comparison of sugammadex and sugammadex-neostigmine combination in the antagonism of moderate neuromuscular block

Conditions: Residual Neuromuscular Block; Neuromuscular Blockade Monitoring

Summary: in this prospective randomized controlled study the investigators compare the sugammadex-neostigmine combination and single dose sugammadex in terms of side effects and cost for the antagonism of moderate neuromuscular block induced by rocuronium.

sugammadex is a novel drug used to reverse neuromuscular blockade. it shows its effect by binding with steroid neuromuscular agents at a ratio of 1:1. compared to anticholinesterase and other neuromuscular reverse agents, sugammadex shows less cholinergic side effects and less residual muscle relaxation. besides all these, sugammadex reverses neuromuscular blockade very quickly. in addition to these benefits, it has side effects such as hypersensitivity and this side effect can be seen more at high doses. in addition, sugammadex is more costly than other neuromuscular reverse agents. in this prospective randomized controlled study the investigators compare the sugammadex-neostigmine combination and single dose sugammadex in terms of side effects and cost for the antagonism of moderate neuromuscular block induced by rocuronium.

Eligibility criteria:
inclusion criteria: * elective general anesthesia * female gender * between the ages of 18-65 exclusion criteria: * asa ≥ 3 * pregnancy * contraindication to use of anesthetic drugs * kidney failure * liver failure * heart failure * bmi \ 35 kg/m2 * anticipated difficult airway * neuromuscular disease * use of drugs that impair neuromuscular transmission * patients who develop unexpected massive hemorrhage * those who do not have the ability to read, understand and sign the consent form * refusal of patient

Keywords: sugammadex neostigmine neuromuscular blockade monitoring postoperative nausea and vomiting delayed emergence from anesthesia postoperative complications rocuronium residual neuromuscular block